# US 2021/0003579 A1 · Method for assisting determination of efficacy of immune checkpoint inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0003579 A1
- Document ID: US20210003579A1
- Status: Published application
- Kind: A1
- Application number: 17/029,361
- Filed: 2020-09-23
- Published: 2021-01-07
- Earliest claimed: 2018-03-27
- Assignees: Kyoto University; Kinki University; Ono Pharmaceutical Co., Ltd.; Sysmex Corporation
- Applicants: Kyoto University; Kinki University; Ono Pharmaceutical Co., Ltd.; Sysmex Corporation
- Inventors: Tasuku HONJO; Kenji CHAMOTO; Hidetoshi HAYASHI; Kazuhiko NAKAGAWA; Megumi GOTO; Hitoshi UGA
- Web page: https://patentgrep.com/patent/US20210003579A1

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/2818: {against CD28 or CD152}
- G01N 33/5752: of the lungs
- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/70521: CD28, CD152
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

## Claims

### Claim 1

A method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising:
measuring a free protein marker in a liquid sample collected from a subject; and
determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein
the free protein marker is at least one selected from the group consisting of free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the free protein marker is at least two selected from the group consisting of free CTLA-4, free PD-1 and free PD-L1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the free protein marker is free CTLA-4, free PD-1 and free PD-L1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein, in the determining, it is determined that the immune checkpoint inhibitor is effective for the subject when a measurement value for the free protein marker which is acquired in the measuring is lower than a predetermined threshold value corresponding to each free protein marker.

### Claim 5 (depends on 1)

The method according to claim 1, wherein
the free protein marker is two selected from the group consisting of free CTLA-4, free PD-1 and free PD-L1, and
it is determined that the immune checkpoint inhibitor is effective for the subject when a measurement value for one of the free protein markers is lower than a threshold value corresponding to the one free protein marker and a measurement value for the other free protein marker is lower than a threshold value corresponding to the other free protein marker.

### Claim 6 (depends on 1)

The method according to claim 1, wherein
the free protein marker is free CTLA-4, free PD-1 and free PD-L1, and
it is determined that the immune checkpoint inhibitor is effective for the subject when a measurement value for free CTLA-4 is lower than a threshold value corresponding to free CTLA-4, a measurement value for free PD-1 is lower than a threshold value corresponding to free PD-1, and a measurement value for free PD-L1 is lower than a threshold value corresponding to free PD-L1.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the subject is a cancer patient who is determined that the ratio of PD-L1-positive tumor cells is smaller than a predetermined value by immunostaining of a tumor tissue collected from the subject.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the subject is a lung cancer patient, an esophageal cancer patient or an endometrial cancer patient.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the liquid sample is a blood sample.

### Claim 10 (depends on 1)

The method according to claim 1, further comprising
administering the immune checkpoint inhibitor to the subject who is determined that the immune checkpoint inhibitor is effective in the determining.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the immune checkpoint inhibitor comprises at least one selected from the group consisting of an anti-PD-1 antibody, an anti-CTLA-4 antibody and an anti-PD-L1 antibody as an active ingredient.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the immune checkpoint inhibitor comprises an anti-PD-1 antibody as an active ingredient.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the immune checkpoint inhibitor comprises nivolumab or pembrolizumab as an active ingredient.

### Claim 14

A method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising:
measuring free Cytotoxic T lymphocyte antigen-4 (CTLA-4) and measuring free Programmed cell death-1 (PD-1) in a liquid sample collected from a subject; and
determining the efficacy of the immune checkpoint inhibitor in the subject based on results of the measurements.

### Claim 15 (depends on 14)

The method according to claim 14, wherein, in the determining, it is determined that the immune checkpoint inhibitor is effective for the subject when a measurement value for CTLA-4 which is acquired in the measuring is lower than a predetermined threshold value corresponding to CTLA-4 and a measurement value for PD-1 which is acquired in the measuring is lower than a predetermined threshold value corresponding to PD-1.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the subject is a cancer patient who is determined that the ratio of PD-L1-positive tumor cells is smaller than a predetermined value by immunostaining of a tumor tissue collected from the subject.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the subject is a lung cancer patient, an esophageal cancer patient or an endometrial cancer patient.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the liquid sample is a blood sample.

### Claim 19 (depends on 14)

The method according to claim 14, further comprising
administering the immune checkpoint inhibitor to the subject who is determined that the immune checkpoint inhibitor is effective in the determining.

### Claim 20

A method for treating a cancer, the method comprising:
administering an immune checkpoint inhibitor to a cancer patient who is determined as a patient for whom the immune checkpoint inhibitor is effective based on a result of a measurement of a free protein marker in a liquid sample collected from the cancer patient,
wherein the free protein marker is at least one selected from the group consisting of free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).
